Accretion Pharmaceuticals share price
NSE: ACCPLPharmaceuticals & Biotechnology
Accretion Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2025 · Issue price ₹101
Last close ₹181.00down ₹4.00 (2.16%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹185.00.
29 Oct: open ₹181.00, high ₹181.00, low ₹181.00
52-week range of traded prices to 29 Oct 2026
₹54.60Low, 7 Nov 2025₹220.00High, 30 Sep 2026
- Next results date: the board meets on 31 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹201 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.23
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,600100.0% delivered
Results
Standalone; ₹ crore.Accretion Pharmaceuticals half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +56.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +42.3%
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹46 Crup 4.93%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹4.92 Crup 3.43%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 10.7%
Revenue by half year
Peak revenue ₹46 Cr, half year to Mar 2026; lowest ₹19 Cr, half year to Sep 2024
Net profit by half year, a loss in red
| ₹ crore | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 18.6 | 38.8 | 43.7 | 45.9 |
| Net profit | 2.5 | 4.3 | 4.8 | 4.9 |
| Net margin | 13.3% | 11.2% | 10.9% | 10.7% |
Standalone. The 4 half years from Sep 2024, the first on record. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹90 Crup 56.21%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹9.67 Crup 42.31%
- Net margin
- 10.8%
Revenue by year
Peak revenue ₹90 Cr, year to Mar 2026; lowest ₹57 Cr, year to Mar 2025
Net profit by year, a loss in red
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 57.4 | 89.6 |
| Net profit | 6.8 | 9.7 |
| Net margin | 11.8% | 10.8% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Accretion Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 79% of 238 trading days over the last year.
LowestHighest
Its median12.75Industry median28.38
Price to book
At or below today's level on 78% of 227 trading days since Nov 2025.
LowestHighest
Its median2.43Industry median2.97
Accretion Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Accretion Pharmaceuticals in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Gennex LaboratoriesGENNEX | 218 | 11.85 | 0.98 | +24.1% | +7.3% | 9.0% | 7.0% | 0.00% |
 Sat Kartar LifeSATKARTAR | 212 | 11.12 | 2.44 | – | – | 26.3% | – | 0.52% |
 Accretion NutravedaANL | 210 | 41.43 | 5.92 | – | – | 14.3% | – | 0.00% |
 Sanjivani ParanteralSANJIVIN | 207 | – | 4.29 | +13.2% | – | – | 20.2% | 0.00% |
 Nectar LifesciencesNECLIFE | 201 | – | 0.34 | −99.7% | – | −31.9% | −15.4% | 0.00% |
 Achyut HealthcareACHYUT | 197 | – | 5.59 | – | – | – | 0.2% | 0.00% |
 Kerala AyurvedaKERALAYUR | 191 | – | – | +10.4% | – | −257.3% | −24.1% | 0.00% |
 Syschem (India)SYSCHEM | 189 | – | 1.35 | +40.3% | – | – | 10.4% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Accretion Pharmaceuticals announcements
Oct 2026
24 Oct · Board meeting
10 Oct · Amendment to AOA/MOA
10 Oct · Meeting
10 Oct · Meeting
Sep 2026
9 Sep · Meeting
Accretion Pharmaceuticals share price by year
Each calendar year to 2025.Accretion Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 87.85 | – | 101.05 | 54.60 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 21 May 2025.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 181.95 | 185.00 | 181.95 | 185.00 | 182.99 | 4,800 | 100.0% |
| 27 Oct 2026 | 186.00 | 186.00 | 185.00 | 185.00 | 185.33 | 3,600 | 100.0% |
| 26 Oct 2026 | 173.15 | 186.00 | 173.15 | 186.00 | 176.85 | 14,400 | 100.0% |
| 23 Oct 2026 | 189.20 | 190.00 | 182.10 | 182.10 | 188.43 | 7,200 | 100.0% |
| 22 Oct 2026 | 183.30 | 190.00 | 183.30 | 189.30 | 186.43 | 9,600 | 87.5% |
| 21 Oct 2026 | 183.65 | 192.85 | 183.60 | 192.85 | 186.03 | 4,800 | 75.0% |
| 13 Oct 2026 | 198.90 | 198.90 | 193.20 | 193.20 | 196.01 | 4,800 | 100.0% |
| 12 Oct 2026 | 190.00 | 190.00 | 190.00 | 190.00 | 190.00 | 1,200 | 100.0% |
| 9 Oct 2026 | 187.85 | 189.00 | 180.00 | 188.95 | 188.39 | 48,000 | 90.0% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ACCPL
- ISIN
- INE0T8T01010
- Industry
- Pharmaceuticals & Biotechnology